



HOUSE COMMITTEE ON WAYS & MEANS CHAIRMAN RICHARD E. NEAL

KEY DRUG PRICING FACTS FOR VA-07 (Rep. Abigail Spanberger) *Know Your District*

In VA-07, there are **96,665 people enrolled in a Medicare Part D plan** and **613,804 people enrolled in private health insurance** – all of whom stand to benefit from the passage of *H.R. 3 The Lower Drug Costs Now Act*.

Source of Prescription Drug Coverage	VA-07 Residents	
Medicare Prescription Drug Plan (PDP)	9.2%	(72,358 People)
Medicare Advantage Prescription Drug (MA-PD)	3.1%	(24,170 People)
Medicare Part D (Any Plan)	12.2%	(96,665 People)
Private Health Insurance	77.7%	(613,804 People)

Source: Committee tabulations of U.S. Census Bureau, 2017 American Community Survey 1-year estimates

Note: Some insurance categories include people who have multiple sources of coverage. Some insurance categories are not included. Therefore, totals will not sum up to 100%.

Cancer Medications

There are an estimated **15 million Americans living with cancer**, including **45,440 annual cancer diagnoses in Virginia**. In 2019, an estimated **15,200 Virginia residents will die of cancer**. Most cancer medications cost patients **over \$100,000 annually** in the U.S., which is why 90 percent of Americans say cancer drugs are too expensive.

BREAST CANCER

In 2019, an estimated **7,120 women in Virginia will be diagnosed with breast cancer**.

H.R. 3 can lower the average total cost of the breast cancer medication Ibrance by 65% from **\$69,000 to \$23,900 per year**.

Source: Committee tabulations of American Cancer Society, 2019 Cancer Statistics Center, and 2018 pharmaceutical price data from recognized price sources.

LEUKEMIA

In 2019, an estimated **1,400 people in Virginia will be diagnosed with leukemia**.

H.R. 3 can lower the average total cost of the leukemia medication Tasigna by 71% from **\$93,700 to \$27,400 per year**.

Source: Committee tabulations of American Cancer Society, 2019 Cancer Statistics Center, and 2018 pharmaceutical price data from recognized price sources.

PROSTATE CANCER

In 2019, an estimated **5,440 people in Virginia will be diagnosed with prostate cancer**.

H.R. 3 can lower the average total cost of the prostate cancer medication Zytiga by 66% from **\$109,500 to \$37,400 per year**.

Source: Committee tabulations of American Cancer Society, 2019 Cancer Statistics Center, and 2018 pharmaceutical price data from recognized price sources.



H.R. 3 will Reduce Drug Costs for Millions of Americans

ARTHRITIS

21.6% of Virginia residents have arthritis, 26.7% of whom experience severe joint pain because of it. H.R. 3 can lower their total costs on most arthritis drugs from about **\$40,000 to \$10,000 per year**.

Source: Arthritis Foundation, Committee tabulations of 2018 pharmaceutical price data from recognized price sources.

ASTHMA

About 8.9% or 581,200 Virginia residents live with asthma. H.R. 3 can lower their total costs on most asthma drugs from about **\$1,400 to \$270 per year**.

Source: Centers for Disease Control and Prevention, Committee tabulations of 2018 pharmaceutical price data from recognized price sources.

HIV/AIDS

In 2015, 868 Virginia residents were diagnosed with HIV. H.R. 3 can lower their total costs on most HIV drugs from about **\$15,000 to \$6,000 per year**.

Source: Centers for Disease Control and Prevention, Committee tabulations of 2018 pharmaceutical price data from recognized price sources.

MULTIPLE SCLEROSIS

One million people are living with Multiple Sclerosis (MS) in the United States. H.R. 3 can lower their total costs on most MS drugs from about **\$40,000 to \$13,000 per year**.

Source: MS Society, Committee tabulations of 2018 pharmaceutical price data from recognized price sources.

Insulin

30.3 million Americans live with diabetes, including **687,972 people in Virginia**. Over the past decade, the price of insulin has **increased 197 percent**, and Medicare Part D spending on insulin has **increased 840 percent**.

DIABETES

In Virginia, there are an estimated **687,972 people living with diabetes**.

9.6% of Virginia residents live with diabetes.

Source: Committee tabulations of Center for Disease Control and Prevention, 2017 Diagnosed Diabetes Statistics, and 2018 pharmaceutical price data from recognized price sources.

INSULIN COSTS

For the most commonly used insulin medications, Virginia residents spend anywhere from **\$1,200 to \$20,000 annually**.

H.R. 3 can lower the average total cost of the insulin NovoLOG Flexpen by 76% from about **\$19,800 to \$4,800 per year**.

Under H.R. 3, Virginia residents could spend **3.5 times less on insulin**.

Under H.R. 3, some commonly used insulins can cost as little as **\$400 per year**.

Source: Committee tabulations of 2018 pharmaceutical price data from recognized price sources.